相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation Results of a Two-Part Phase 3 Clinical Trial
Jane C. Davies et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells
Zsolt Bene et al.
FRONTIERS IN PHARMACOLOGY (2021)
Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids
Iris A. L. Silva et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
CFTR: New insights into structure and function and implications for modulation by small molecules
Bertrand Kleizen et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Cystic fibrosis in the year 2020: A disease with a new face
Kris De Boeck
ACTA PAEDIATRICA (2020)
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis
Heledd H. Jarosz-Griffiths et al.
ELIFE (2020)
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Miqueias Lopes-Pacheco
FRONTIERS IN PHARMACOLOGY (2020)
Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta
Nara Liessi et al.
JCI INSIGHT (2020)
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
Bela Nagy et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients
Michael Bitonti et al.
JOURNAL OF PEDIATRIC HEALTH CARE (2019)
Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations
Margarida Amaral et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against Pseudomonas aeruginosa
Do-Yeon Cho et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2019)
Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells
Manon Ruffin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts
Damien Adam et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld et al.
LANCET RESPIRATORY MEDICINE (2018)
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies
Mark T. Jennings et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)
Role of CFTR in epithelial physiology
Vinciane Saint-Criq et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
New horizons for cystic fibrosis treatment
Isabelle Fajac et al.
PHARMACOLOGY & THERAPEUTICS (2017)
The changing epidemiology and demography of cystic fibrosis
Anne L. Stephenson et al.
PRESSE MEDICALE (2017)
New treatments targeting the basic defects in cystic fibrosis
Isabelle Fajac et al.
PRESSE MEDICALE (2017)
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
Michael W. Konstan et al.
LANCET RESPIRATORY MEDICINE (2017)
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
Katherine B. Hisert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
Carlos E. Milla et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Epidemiology of Cystic Fibrosis
Kimberly A. Spoonhower et al.
CLINICS IN CHEST MEDICINE (2016)
Cystic Fibrosis A Review of Associated Phenotypes, Use of Molecular Diagnostic Approaches, Genetic Characteristics, Progress, and Dilemmas
Marie-Luise Brennan et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
Miqueias Lopes-Pacheco
FRONTIERS IN PHARMACOLOGY (2016)
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
Jane C. Davies et al.
LANCET RESPIRATORY MEDICINE (2016)
Progress in therapies for cystic fibrosis
Kris De Boeck et al.
LANCET RESPIRATORY MEDICINE (2016)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors
George M. Solomon et al.
PEDIATRIC PULMONOLOGY (2015)
New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls
Scott C. Bell et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease
Peter J. Barry et al.
CHEST (2014)
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
Kris De Boeck et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
Michael P. Boyle et al.
LANCET RESPIRATORY MEDICINE (2014)
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)
Edward F. McKone et al.
LANCET RESPIRATORY MEDICINE (2014)
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Jane C. Davies et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Patrick A. Flume et al.
CHEST (2012)
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
J. P. Clancy et al.
THORAX (2012)
Physiology of Epithelial Chloride and Fluid Secretion
Raymond A. Frizzell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Patient-, Provider-, and Clinic-Level Predictors of Unrecognized Elevated Blood Pressure in Children
Tammy M. Brady et al.
PEDIATRICS (2010)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
分享论文
